26
Participants
Start Date
April 1, 2019
Primary Completion Date
July 1, 2021
Study Completion Date
July 1, 2021
Switch to E/C/FTC/TAF daily
"If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
UCLA CARE Center, Los Angeles
Collaborators (1)
Gilead Sciences
INDUSTRY
University of California, Los Angeles
OTHER